Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Jun 1;108(6):1671-1675.
doi: 10.3324/haematol.2022.281963.

IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

Maria Cristina Pirosa  1 , Marianna Sassone  2 , Barbara Kiesewetter  3 , Armando Lopez Guillermo  4 , Liliana Devizzi  5 , Eva Domingo Domènech  6 , Alessandra Tucci  7 , Donato Mannina  8 , Michele Merli  9 , Antonio Salar  10 , Carlo Visco  11 , Fabiana Esposito  12 , Luisella Bonomini  13 , Emanuele Zucca  14 , Andrés J M Ferreri  2 , Markus Raderer  3
Affiliations
Clinical Trial

IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma

Maria Cristina Pirosa et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Response of patients with refractory/relapsed mantle zone lymphoma to treatment with the CLEO regimen. (A) Waterfall plot of percent change in radiologically measurable disease by primary anatomic site. The chart includes all the 28 evaluable patients with extra-gastric localizations and one patient who had gastric lymphoma with additional radiologically measurable disease (perigastric adenopathy). In the remaining nine evaluable patients, all with gastric lymphoma, response was assessed only by endoscopy and repeat biopsy, hence, they cannot be included in the graph. (B) Kaplan-Meier estimate of response duration in the 19 patients who achieved an objective response (complete or partial).
See this image and copyright information in PMC

References

    1. Zucca E, Arcaini L, Buske C, et al. . Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17-29. - PubMed
    1. Kiesewetter B, Troch M, Dolak W, et al. . A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013;98(3):353-356. - PMC - PubMed
    1. Ferreri AJM, Cecchetti C, Kiesewetter B, et al. . Clarithromycin as a "repurposing drug" against MALT lymphoma. Br J Haematol. 2018;182(6):913-915. - PubMed
    1. Pokorny A, Kiesewetter B, Raderer M. Experience with clarithromycin as antineoplastic therapy for extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) outside of clinical trials: real-world data from the University of Vienna. Hematol Oncol. 2020;38(3):409-411. - PubMed
    1. Ghosh N, Tucker N, Zahurak M, Wozney J, Borrello I, Huff CA. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. Am J Hematol. 2014;89(8):E116-120. - PMC - PubMed

MeSH terms

Associated data